Patent ID: 7807364
Filing Date: 2010-10-05
Classification: A61K,A61P,C07K,C12Q

Abstract:
1. A method for determining whether a human ovarian cancer patient is more or less suitably treated by a therapy comprising administration of a bevacizumab antibody or an antibody that binds to the same epitope on VEGF as the bevacizumab, and cyclophosphamide comprising determining the genotype of IL-8 at position −251 present in a nucleic acid sample obtained from the patient, wherein the patient is more suitably treated if the patient's genotype is T/T at position −251 of IL-8 as compared to a patient having a genotype of A/A or A/T at position −251 of IL-8 or the patient is less suitably treated if the patient's genotype is A/A or A/T at position −251 of IL-8 as compared to a patient having a genotype of T/T at position −251 of IL-8.